Literature DB >> 23408609

Genetic and functional characterization of the N-terminal region of the hepatitis C virus NS2 protein.

Cynthia de la Fuente1, Zachary Goodman, Charles M Rice.   

Abstract

The hepatitis C virus (HCV) NS2 protein has dual roles within the HCV life cycle. While well characterized as an autoprotease that cleaves the NS2/NS3 junction, NS2, primarily via its N-terminal region, is also involved in virion morphogenesis. In order to map the determinants necessary for infectious virus production and gain further insight into the multiple points at which NS2 may impact this process, a detailed mutational analysis of residues spanning amino acids (aa) 1 to 92 was performed. Initial block mutagenesis (5 or 7 amino acid residues) in both bicistronic and monocistronic HCV cell culture-based (HCVcc) genomes revealed that all but two blocks had various levels of impaired infectious virus production. None of these mutations affected RNA replication, indicating that the N-terminal region of NS2 is not required for NS2-3 processing and replicase assembly. Fine mapping identified 29 critical residues that, when mutated, yielded at least a 1 log decrease in infectious virus titers. These mutants were characterized further with respect to release of extracellular HCV RNA and core, intracellular infectivity, thermal stability of virus particles, and NS2 interactions. While the most severely debilitated mutants were impaired early in the assembly process, which is in agreement with previous reports, others targeted later steps of virus production, most notably egress. Thus, in addition to participating in early steps in virion assembly, this comprehensive mutagenesis study suggests yet another role for NS2 in later steps in virus production.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23408609      PMCID: PMC3624385          DOI: 10.1128/JVI.03174-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Two hepatitis C virus glycoprotein E2 products with different C termini.

Authors:  H Mizushima; M Hijikata; S Asabe; M Hirota; K Kimura; K Shimotohno
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

Review 2.  Architects of assembly: roles of Flaviviridae non-structural proteins in virion morphogenesis.

Authors:  Catherine L Murray; Christopher T Jones; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2008-09       Impact factor: 60.633

3.  Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses.

Authors:  J Dubuisson; H H Hsu; R C Cheung; H B Greenberg; D G Russell; C M Rice
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Complex processing and protein:protein interactions in the E2:NS2 region of HCV.

Authors:  M J Selby; E Glazer; F Masiarz; M Houghton
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

5.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

6.  Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Authors:  Troels K H Scheel; Judith M Gottwein; Tanja B Jensen; Jannick C Prentoe; Anne M Hoegh; Harvey J Alter; Jesper Eugen-Olsen; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

7.  Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly.

Authors:  Vlastimil Jirasko; Roland Montserret; Nicole Appel; Anne Janvier; Leah Eustachi; Christiane Brohm; Eike Steinmann; Thomas Pietschmann; Francois Penin; Ralf Bartenschlager
Journal:  J Biol Chem       Date:  2008-07-21       Impact factor: 5.157

8.  Regulation of hepatitis C virion production via phosphorylation of the NS5A protein.

Authors:  Timothy L Tellinghuisen; Katie L Foss; Jason Treadaway
Journal:  PLoS Pathog       Date:  2008-03-21       Impact factor: 6.823

9.  CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.

Authors:  Jeroen Witteveldt; Matthew J Evans; Julia Bitzegeio; George Koutsoudakis; Ania M Owsianka; Allan G N Angus; Zhen-Yong Keck; Steven K H Foung; Thomas Pietschmann; Charles M Rice; Arvind H Patel
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

10.  Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions.

Authors:  Eike Steinmann; Francois Penin; Stephanie Kallis; Arvind H Patel; Ralf Bartenschlager; Thomas Pietschmann
Journal:  PLoS Pathog       Date:  2007-07       Impact factor: 6.823

View more
  13 in total

Review 1.  The ins and outs of hepatitis C virus entry and assembly.

Authors:  Brett D Lindenbach; Charles M Rice
Journal:  Nat Rev Microbiol       Date:  2013-09-10       Impact factor: 60.633

2.  NS2 proteins of GB virus B and hepatitis C virus share common protease activities and membrane topologies.

Authors:  Célia Boukadida; Caroline Marnata; Roland Montserret; Lisette Cohen; Brigitte Blumen; Jérôme Gouttenoire; Darius Moradpour; François Penin; Annette Martin
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

3.  Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.

Authors:  Christian K Mathiesen; Jannick Prentoe; Luke W Meredith; Tanja B Jensen; Henrik Krarup; Jane A McKeating; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.

Authors:  Vanessa M Cowton; Allan G N Angus; Sarah J Cole; Christina K Markopoulou; Ania Owsianka; James I Dunlop; Deborah E Gardner; Thomas Krey; Arvind H Patel
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

5.  NS2 is dispensable for efficient assembly of hepatitis C virus-like particles in a bipartite trans-encapsidation system.

Authors:  Matthew J Bentham; Najat Marraiki; Christopher J McCormick; David J Rowlands; Stephen Griffin
Journal:  J Gen Virol       Date:  2014-07-14       Impact factor: 3.891

6.  A conserved NS3 surface patch orchestrates NS2 protease stimulation, NS5A hyperphosphorylation and HCV genome replication.

Authors:  Olaf Isken; Ulrike Langerwisch; Vlastimil Jirasko; Dirk Rehders; Lars Redecke; Harish Ramanathan; Brett D Lindenbach; Ralf Bartenschlager; Norbert Tautz
Journal:  PLoS Pathog       Date:  2015-03-16       Impact factor: 6.823

7.  Hepatitis C Virus Proteins Interact with the Endosomal Sorting Complex Required for Transport (ESCRT) Machinery via Ubiquitination To Facilitate Viral Envelopment.

Authors:  Rina Barouch-Bentov; Gregory Neveu; Fei Xiao; Melanie Beer; Elena Bekerman; Stanford Schor; Joseph Campbell; Jim Boonyaratanakornkit; Brett Lindenbach; Albert Lu; Yves Jacob; Shirit Einav
Journal:  mBio       Date:  2016-11-01       Impact factor: 7.867

8.  Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein.

Authors:  Yimin Gao; Xiaoyan Yu; Binbin Xue; Fei Zhou; Xiaohong Wang; Darong Yang; Nianli Liu; Li Xu; Xiaohong Fang; Haizhen Zhu
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

9.  HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.

Authors:  Jannick Prentoe; Lieven Verhoye; Rodrigo Velázquez Moctezuma; Caroline Buysschaert; Ali Farhoudi; Richard Wang; Harvey Alter; Philip Meuleman; Jens Bukh
Journal:  Gut       Date:  2015-11-20       Impact factor: 23.059

10.  Release of Infectious Hepatitis C Virus from Huh7 Cells Occurs via a trans-Golgi Network-to-Endosome Pathway Independent of Very-Low-Density Lipoprotein Secretion.

Authors:  Jamel Mankouri; Cheryl Walter; Hazel Stewart; Matthew Bentham; Wei Sun Park; Won Do Heo; Mitsunori Fukuda; Stephen Griffin; Mark Harris
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.